Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $656.29 million. The enterprise value is $1.02 billion.
Important Dates
The next estimated earnings date is Tuesday, March 11, 2025, before market open.
| Earnings Date | Mar 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 65.37 million shares outstanding. The number of shares has increased by 2.56% in one year.
| Current Share Class | 65.37M |
| Shares Outstanding | 65.37M |
| Shares Change (YoY) | +2.56% |
| Shares Change (QoQ) | +1.88% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 32.41% |
| Float | 33.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 20.42 |
| PS Ratio | 1.16 |
| Forward PS | 1.10 |
| PB Ratio | 4.41 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.59 |
| P/OCF Ratio | 21.99 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 20.21, with an EV/FCF ratio of 35.06.
| EV / Earnings | n/a |
| EV / Sales | 1.83 |
| EV / EBITDA | 20.21 |
| EV / EBIT | 32.52 |
| EV / FCF | 35.06 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 2.17.
| Current Ratio | 1.41 |
| Quick Ratio | 0.78 |
| Debt / Equity | 2.17 |
| Debt / EBITDA | 7.15 |
| Debt / FCF | 13.95 |
| Interest Coverage | 0.78 |
Financial Efficiency
Return on equity (ROE) is -24.76% and return on invested capital (ROIC) is 3.16%.
| Return on Equity (ROE) | -24.76% |
| Return on Assets (ROA) | 2.48% |
| Return on Capital (ROIC) | 3.16% |
| Revenue Per Employee | $572,228 |
| Profits Per Employee | -$40,703 |
| Employee Count | 970 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | -6.59M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +106.58% in the last 52 weeks. The beta is 0.85, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +106.58% |
| 50-Day Moving Average | 10.99 |
| 200-Day Moving Average | 8.76 |
| Relative Strength Index (RSI) | 45.71 |
| Average Volume (20 Days) | 345,409 |
Short Selling Information
The latest short interest is 1.02 million, so 1.56% of the outstanding shares have been sold short.
| Short Interest | 1.02M |
| Short Previous Month | 975,982 |
| Short % of Shares Out | 1.56% |
| Short % of Float | 3.06% |
| Short Ratio (days to cover) | 3.52 |
Income Statement
In the last 12 months, Bioventus had revenue of $555.06 million and -$39.48 million in losses. Loss per share was -$0.62.
| Revenue | 555.06M |
| Gross Profit | 371.87M |
| Operating Income | 31.31M |
| Pretax Income | -48.54M |
| Net Income | -39.48M |
| EBITDA | 50.39M |
| EBIT | 31.31M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $43.07 million in cash and $405.07 million in debt, giving a net cash position of -$362.00 million or -$5.54 per share.
| Cash & Cash Equivalents | 43.07M |
| Total Debt | 405.07M |
| Net Cash | -362.00M |
| Net Cash Per Share | -$5.54 |
| Equity (Book Value) | 186.83M |
| Book Value Per Share | 2.28 |
| Working Capital | 87.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $29.85 million and capital expenditures -$801,000, giving a free cash flow of $29.05 million.
| Operating Cash Flow | 29.85M |
| Capital Expenditures | -801,000 |
| Free Cash Flow | 29.05M |
| FCF Per Share | $0.44 |
Full Cash Flow StatementMargins
Gross margin is 67.00%, with operating and profit margins of 5.64% and -7.11%.
| Gross Margin | 67.00% |
| Operating Margin | 5.64% |
| Pretax Margin | -10.41% |
| Profit Margin | -7.11% |
| EBITDA Margin | 9.08% |
| EBIT Margin | 5.64% |
| FCF Margin | 5.23% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.56% |
| Shareholder Yield | -2.56% |
| Earnings Yield | -6.02% |
| FCF Yield | 4.43% |
Analyst Forecast
The average price target for Bioventus is $15.00, which is 49.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 49.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 0.72 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.72 |
| Piotroski F-Score | 6 |